Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records

被引:133
作者
Boyle, PJ
King, AB
Olansky, L
Marchetti, A
Lau, H
Magar, R
Martin, J
机构
[1] Hlth Econ Res, Secaucus, NJ 07094 USA
[2] Univ New Mexico, Sch Med, Dept Internal Med, Albuquerque, NM 87131 USA
[3] Univ Calif San Francisco, Sch Med, Dept Family & Community Med, San Francisco, CA 94143 USA
[4] Univ Oklahoma, Sch Med, Sect Endocrinol Metab & Hypertens, Oklahoma City, OK USA
关键词
type; 2; diabetes; thiazolidinediones; blood lipids; glycemic control; hyperglycemia; hyperlipidemia;
D O I
10.1016/S0149-2918(02)85040-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background. The antihyperglycemic effects of pioglitazone hydrochloride and rosiglitazone maleate are well documented. The results of clinical trials and observational studies have suggested, however, that there are individual differences in the effects of these drugs on blood lipid levels. Objective: The present study evaluated the effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus. Methods: This was a retrospective review of randomly selected medical records from 605 primary care practices in the United States in which adults with type 2 diabetes received pioglitazone or rosiglitazone between August 1, 1999, and August 31, 2000. The outcome measures were mean changes in serum concentrations of triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and glycosylated hemoglobin (HbA(lc)) values. Results: Treatment with pioglitazone was associated with a reduction in mean TG of 55.17 mg/dL. a reduction in TC of 8.45 mg/dL, an increase in HDL-C of 2.65 mg/dL, and a reduction in LDL-C of 5.05 mg/dL. Treatment with rosiglitazone was associated with a reduction in mean TG of 13.34 mg/dL, an increase in TC of 4.81 mg/dL, a reduction in HDL-C of 0.12 mg/dL, and an increase in LDL-C of 3.56 mg/dL. With the exception of HDL-C, the differences in mean changes in lipid parameters between treatment groups were statistically significant (P < 0.001, pioglitazone vs rosiglitazone). Reductions in HbA(lc) were statistically equivalent between treatments (1.04% pioglitazone, 1.18% rosiglitazone). Conclusions: Treatment with pioglitazone was associated with greater beneficial effects on blood lipid levels than treatment with rosiglitazone, whereas glycemic control was equivalent between the 2 treatments.
引用
收藏
页码:378 / 396
页数:19
相关论文
共 53 条
  • [11] Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes melitus: A randomized, placebo-controlled study
    Einhorn, D
    Rendell, M
    Rosenzweig, J
    Egan, JW
    Mathisen, AL
    Schneider, RL
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (12) : 1395 - 1409
  • [12] Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia
    Eriksson, P
    Nilsson, L
    Karpe, F
    Hamsten, A
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (01) : 20 - 26
  • [13] Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus - A randomized controlled trial
    Fonseca, V
    Rosenstock, J
    Patwardhan, R
    Salzman, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (13): : 1695 - 1702
  • [14] Hepatic failure in a patient taking rosiglitazone
    Forman, LM
    Simmons, DA
    Diamond, RH
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 132 (02) : 118 - 121
  • [15] Rosiglitazone and hepatic failure
    Freid, J
    Everitt, D
    Boscia, J
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 132 (02) : 164 - 164
  • [16] Gegick C G, 2001, Endocr Pract, V7, P162
  • [17] Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone
    Gitlin, N
    Julie, NL
    Spurr, CL
    Lim, KN
    Juarbe, HM
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (01) : 36 - 38
  • [18] *GLAX, 2001, AV ROS MAL TABL PACK
  • [19] Thiazolidinediones for type 2 diabetes - No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4
    Glazer, NB
    Cheatham, WW
    [J]. BRITISH MEDICAL JOURNAL, 2001, 322 (7280) : 235 - 236
  • [20] Rosiglitazone and liver failure
    Isley, WL
    Oki, JC
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 133 (05) : 393 - 393